PhoreMost and NeoPhore Receive Innovate UK Funding to Support Development of a Novel Small-Molecule Cancer Immunotherapy Programme 27th April 2018
PhoreMost and Sixth Element Capital Announce Creation and Investment in NeoPhore, an Immuno-Oncology Company 15th November 2017
PhoreMost Ltd and University of Cambridge collaborate to identify innovative drug targets for neurodegenerative disease 12th October 2016